Gilard Vianney, Tebani Abdellah, Dabaj Ivana, Laquerrière Annie, Fontanilles Maxime, Derrey Stéphane, Marret Stéphane, Bekri Soumeya
Department of Neurosurgery, Rouen University Hospital, 76000 Rouen, France.
Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France.
J Pers Med. 2021 Apr 1;11(4):258. doi: 10.3390/jpm11040258.
Glioblastoma is the most common malignant brain tumor in adults. The current management relies on surgical resection and adjuvant radiotherapy and chemotherapy. Despite advances in our understanding of glioblastoma onset, we are still faced with an increased incidence, an altered quality of life and a poor prognosis, its relapse and a median overall survival of 15 months. For the past few years, the understanding of glioblastoma physiopathology has experienced an exponential acceleration and yielded significant insights and new treatments perspectives. In this review, through an original R-based literature analysis, we summarize the clinical presentation, current standards of care and outcomes in patients diagnosed with glioblastoma. We also present the recent advances and perspectives regarding pathophysiological bases as well as new therapeutic approaches such as cancer vaccination and personalized treatments.
胶质母细胞瘤是成人中最常见的恶性脑肿瘤。目前的治疗方法依赖于手术切除以及辅助放疗和化疗。尽管我们对胶质母细胞瘤的发病机制有了更深入的了解,但我们仍然面临着发病率上升、生活质量改变、预后不良、复发以及中位总生存期为15个月的问题。在过去的几年里,对胶质母细胞瘤生理病理学的理解呈指数级加速,并产生了重要的见解和新的治疗前景。在这篇综述中,我们通过基于R语言的原创文献分析,总结了胶质母细胞瘤患者的临床表现、当前的护理标准和治疗结果。我们还介绍了有关病理生理基础的最新进展和前景,以及癌症疫苗接种和个性化治疗等新的治疗方法。